Utility of a Third Heplisav-B Dose in Patients with Inflammatory Bowel Disease without Immunity Following Two-Dose Heplisav-B Vaccination.
Christian KarimeCecily N BlackPedro CortesJoshua Y KwonFreddy CalderaSheena K CrosbyMichael F PiccoJami A KinnucanJana G HashashFrancis A FarrayePublished in: The American journal of gastroenterology (2024)
In patients with IBD lacking HBV immunity despite two-dose Heplisav-B vaccination, administration of a third dose resulted in a 56.7% seroconversion rate. Our results suggest that administration of an additional Heplisav-B dose may be an effective strategy in patients lacking immunity despite primary two-dose vaccination.